Trials are being conducted on a male birth control pill and if successful, the pill would be revolutional.
Akash Bakshi, a San Francisco based biochemist and his team developed a pill codenamed, YCT-529, it works by blocking a vitamin-A-dependent protein essential for sperm growth, temporarily rendering men infertile without affecting their testosterone levels and thereby potentially introducing related side effects.
He said that during Phase 1, human clinical trials showed it was well tolerated, and Bakshi says early results in Phase 2, which is focused on both safety and efficacy, are promising.
Through his company of YourChoice Therapeutics, this could become the first biotech company to bring a hormone-free male birth control pill to market.
